Johnson & Johnson won federal approval Wednesday for a schizophrenia drug derived from another top-selling anti-psychotic medicine.

The Food and Drug Administration said Invega will add to the treatment options for the disabling mental disorder, which affects about 2 million Americans.

Invega, also called paliperidone, is derived from Risperdal. The body breaks down Risperdal to form paliperidone.

Unlike Risperdal, Invega will be sold in extended-release tablet form. The company didn't disclose the drug's cost, saying only that it would be priced competitively with other anti-psychotics.

Schizophrenia is marked by hallucinations, delusions, disordered thinking and movements and cognitive deficits, the FDA said.

NEWS ARCHIVES

2008

• September
• August
• July
• June
• May
• April
• March

2007

• April
• March
• February
• January

2006

• December
• November
• October
• September
• August
• July
• June
• May
• April
• March
• February
• January

2005

• December
• November
• October
• August
• June
• April
• March
• February

2004

• December

NEWSLETTER SIGNUP